Surgery Partners, Inc. (SGRY) Revenue History
Annual and quarterly revenue from 2013 to present
SGRY Revenue Over Time (2013–2025)
SGRY Revenue Growth History
12 of 12 years with positive growth- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- +41.7%
- FY2015 revenue growth
- +138.0%
- FY2016 revenue growth
- +19.3%
- FY2017 revenue growth
- +17.1%
- FY2018 revenue growth
- +32.1%
- FY2019 revenue growth
- +3.4%
- FY2020 revenue growth
- +1.6%
- FY2021 revenue growth
- +19.6%
- FY2022 revenue growth
- +14.1%
- FY2023 revenue growth
- +8.0%
- FY2024 revenue growth
- +13.5%
- FY2025 revenue growth
- +6.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $810.9M | +4.5% |
| Q4 2025 | $885.0M | +2.4% |
| Q3 2025 | $821.5M | +6.6% |
| Q2 2025 | $826.2M | +8.4% |
| Q1 2025 | $776.0M | +8.2% |
| Q4 2024 | $864.4M | +17.5% |
| Q3 2024 | $770.4M | +14.3% |
| Q2 2024 | $762.1M | +14.2% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
SGRY's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
SGRY Revenue Analysis (2013–2025)
Current Revenue & Growth
As of June 22, 2026, Surgery Partners, Inc. (SGRY) generated trailing twelve-month (TTM) revenue of $3.34 billion, reflecting modest growth of +4.5% year-over-year. The most recent quarter (Q1 2026) recorded $810.9 million in revenue, down 8.4% sequentially.
Historical Growth Trajectory
SGRY's 5-year compound annual growth rate (CAGR) stands at +12.2%, indicating consistent double-digit revenue growth. The 3-year CAGR of +9.2% is below the 5-year average, signalling a growth deceleration in recent years. Surgery Partners, Inc.'s highest annual revenue of $3.31 billion was recorded in 2025, an all-time high.
Revenue by Segment
SGRY's revenue is primarily driven by Healthcare Organization, Patient Service (49%), Private Insurance (26%), and Government Revenue (21%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including USPH (+4.0% YoY), SEM (+29.2% YoY), and AMSF (+7.8% YoY) — SGRY has underperformed the peer group in revenue growth. Compare SGRY vs USPH →
SGRY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SGRYCurrent | $3.3B | +4.5% | +12.2% | 11.8% | |
 USPH | $781M | +4.0% | +13.0% | 10.3% | |
 SEM | $5.5B | +29.2% | -0.3% | 6.1% | |
 AMSF | $317M | +7.8% | -1.3% | 18.6% | |
 NHC | $1.5B | +10.9% | +9.0% | 9.5% | |
 ADUS | $1.4B | +19.6% | +13.2% | 9.7% |
SGRY Historical Revenue Data (2013–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.31B | +6.2% | $765.0M | 23.1% | $389.5M | 11.8% |
| 2024 | $3.11B | +13.5% | $745.6M | 23.9% | $348.8M | 11.2% |
| 2023 | $2.74B | +8.0% | $647.5M | 23.6% | $328.0M | 12.0% |
| 2022 | $2.54B | +14.1% | $574.9M | 22.6% | $345.2M | 13.6% |
| 2021 | $2.23B | +19.6% | $491.4M | 22.1% | $302.2M | 13.6% |
| 2020 | $1.86B | +1.6% | $379.8M | 20.4% | $183.0M | 9.8% |
| 2019 | $1.83B | +3.4% | $423.8M | 23.1% | $235.9M | 12.9% |
| 2018 | $1.77B | +32.1% | $410.0M | 23.1% | $77.8M | 4.4% |
| 2017 | $1.34B | +17.1% | $327.4M | 24.4% | $158.2M | 11.8% |
| 2016 | $1.15B | +19.3% | $324.2M | 28.3% | $196.5M | 17.2% |
| 2015 | $959.9M | +138.0% | $290.6M | 30.3% | $144.8M | 15.1% |
| 2014 | $403.3M | +41.7% | $149.1M | 37.0% | $50.8M | 12.6% |
| 2013 | $284.6M | - | $114.8M | 40.3% | $58.2M | 20.5% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SGRY — Frequently Asked Questions
Quick answers to the most common questions about buying SGRY stock.
Is SGRY's revenue growth accelerating or slowing?
SGRY revenue growth is slowing. TTM revenue is $3.3B, up +4.5% year-over-year — below the 5-year CAGR of +12.2%. The deceleration suggests maturing end-markets or increased competition.
What is SGRY's revenue history from 2013 to 2026?
Surgery Partners, Inc. (SGRY) revenue history spans 2013 to 2026. TTM revenue as of 2026 is $3.3B, growing at +4.5% YoY. The 5-year CAGR is +12.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SGRY's long-term revenue growth rate (CAGR)?
Surgery Partners, Inc.'s 5-year revenue CAGR of +12.2% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of +4.5% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SGRY.
Why does SGRY's quarterly revenue fluctuate?
SGRY quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Surgery Partners, Inc.'s revenue data from 2013 to 2026 shows full historical quarterly detail on this page.
How is SGRY's revenue distributed by segment?
SGRY reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SGRY's revenue compare to industry peers?
Surgery Partners, Inc. (SGRY) with TTM revenue of $3.3B and +4.5% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.